An anti-arthritic and 100% vegetarian nutraceutical Cadalmin Green Algal extract
(Cadalmin GAe for use against joint pain and arthritis)
 
 

 

BIOVITA

PATENT DETAILS

The patents registered with respect to the technology are

  1. A process to prepare antioxidant and anti-inflammatory concentrates from brown and red seaweeds and a product therof, Appl. No. 2064/CHE/2010 by K. Chakraborty, …..and G Syda Rao
  2. A product containing anti-inflammatory principles from brown seaweeds and a process therof, Appl. No. 5199/CHE/2012 by K. Chakraborty, …..and G Syda Rao
 
     
  General Introduction of the technology

The present invention discloses a process of preparing a nutraceutical composition with anti-inflammatory properties from seaweeds for use against arthritis. The process involves preparing a mixture of synergistically supporting extracts of plurality of seaweeds. Arthritis represents a major health problem and its global burden is rising at an alarming rate with millions of people suffering from this disease due to various reasons. Many of the allopathic prescriptions include Non Steroidal Anti-Inflammatory Drugs and cyclooxygenase inhibitors used in controlling arthritic conditions have known side effects, especially with long term usage. About 25% of the users experience some kind of side effect and 5% develop serious health consequences such as stomach bleeding, stroke, and acute renal failure. The side-effects of synthetic drugs led the scientists of CMFRI to investigate into natural products for safer and effective alternatives. Seaweeds, which are natural bounty of sea, were found to possess valuable compounds that can offer relief to arthritis and associated joint pain. An intensive research in this area led them to perfect a patented anti-arthritic and 100% vegetarian nutraceutical Cadalmin GAe (Cadalmin Green Algal extract) from these valuable resources. The seaweeds belonging to different species were studied and among them those which possess high bioactivity were carefully processed purified, enriched to obtain Cadalmin Green Algal extract (Cadalmin GAe) which contains useful anti-inflammatory ingredients. Cadalmin GAe is a pure natural and 100% vegetarian product, with its therapeutic values, is an import substitute with an international appeal, providing great market potential especially for the large vegetarian population in India and abroad. The unique biochemical engineering techniques adopted to retain the anti-inflammatory activities in the preparation of Cadalmin GAe assures higher shelf life. The product has been proved to be safe from the acute and chronic toxicity studies on experimental subjects. The hygienically processed active ingredients are housed in low moisture content 100% plant-based Naturecaps capsules that meet the dietary or cultural needs of customers that follow a vegetarian lifestyle.

Performance results Cadalmin GAe provides a unique blend of 100% natural bioactive anti-inflammatory ingredients extracted from marine macroalgae with an ecofriendly “green” technology to combat inflammatory pain and arthritis. These active principles of Cadalmin GAe competitively inhibit pro-inflammatory cyclooxygenase-II and lipooxygenase enzymes, resulting in decreased production of inflammatory prostaglandins and leukotrienes, and its activity was found to be superior to the synthetic non-steroidal anti-inflammatory drugs available in the market. The efficiency of Cadalmin GAe to inhibit these inflammatory enzymes stands at 64-94% as compared to 40-52% for the popular painkiller that was also reported to induce an adverse effect on various metabolic and physiological parameters in human beings. Time dependent in vivo animal model studies on experimental subjects revealed the superior inhibition of inflammatory response to the tune of 73-76% by Cadalmin GAe and its active components as compared to a maximum of 70% for the popular painkiller aspirin, which has several reported side effects. Cadalmin GAe suppresses the edema produced by histamine, and exhibits its antiinflammatory action by means of either inhibiting the synthesis, release or action of anti-inflammatory mediators. Cadalmin GAe has techniques to identify the active components and to concentrate them to have higher activity; it has sustained activity, and no toxicity. Cadalmin GAe is designed to find a unique way to prevent the degradation by air, moisture, heat and light and to maximize the activity. The product is free from deleterious trans fatty acids; free radicals/free radical adducts, low molecular weight carbonyl compounds, and has been proved to be safe from acute and chronic toxicity studies on experimental subjects. The active ingredients in Cadalmin GAe also suppress the build-up of uric acid in hyperuricemic patients.
 
       
  Detailed evaluation using laboratory animal models proved that Cadalmin GAe could be safely taken without any side effects, providing relief to people suffering from arthritis and joint pain. Unique chemical engineering techniques have been adopted to protect the absorption of atmospheric moisture in the active ingredients of Cadalmin GAe, which assures higher shelf life. In-built antioxidant molecules in Cadalmin GAe confer high scavenging activity against deleterious free radicals. Cadalmin GAe is designed to find a unique way to prevent the degradation by air, moisture, heat, light, and to maximize the activity. GAe is chemically engineered to exhibit potentially high radical scavenging activity (98.46 – 99.32%). Cadalmin GAe also effectively prevents lipid peroxidation (4.61 mM MDA equivalent compounds /kg sample). The product is free from carcinogenic trans fatty acids, radical adducts, low molecular weight carbonyl compounds, and inhibit the pathogenic bacterial build-up due to in-build antibacterial principles embedded in the product.  
       
   
     
  The acute toxicity studies and lethal dose of Cadalmin GAe using Wistar rats was carried out to understand its effect on various parameters like mortality, weight change, food consumption, haematological function, liver function, renal function, serum electrolytes, and lipid profile. All the organs were examined visibly for any type of abnormalities in the structure. The final results indicated that Cadalmin GAe (2.5, 1.0 and 0.50 gm/kg body weight ) given to experimental subjects (male and female) did not produce any change in food consumption, water consumption and body weights in rats, indicating that it has no toxicity to these animals. Also it did not produce any biochemical changes related to hepatic and renal function. GAe did not produce any change in haematological parameters such as WBC, RBC, platelet, haemoglobin and differential count. GMe did not produce any weight loss to the animals, or any weight change in organs. Necropsy of the treated animals showed normal appearance of various tissues. These results indicate that Cadalmin GAe did not produce any toxicity to the experimental subjects at concentration (up to 4.0 gm/kg) and time studied (14 days). A long term chronic toxicity studies (90 days) did not produce any change in food consumption, water consumption and body weights in rats, indicating Cadalmin GAe did not produce any toxicity to these animals. Also it did not produce any biochemical changes related to hepatic and renal function. Lipid profile such as cholesterol, HDL-cholesterol, LDL cholesterol and triglycerides levels were unchanged in rats after the trial.

A green remedy Nutraceutical for joint pain and arthritis from sea: Central Marine Fisheries Research Institute’s Cadalmin Green Algal extract (Cadalmin GAe) has been launched at 83rd Annual General Meeting of the ICAR Society at National Agricultural Science Complex, New Delhi

Central Marine Fisheries Research Institute’s Cadalmin Green Algal extract (Cadalmin GAe) has been launched at 83rd Annual General Meeting of the ICAR Society at National Agricultural Science Complex by Dr. Charan Das Mahantji, Hon’ble Minister of State for Agriculture and Food Processing Industries, Govt. of India. Shri Sharad Pawarji, Hon’ble Union Minister of Agriculture and Food Processing Industries and President of the ICAR Society presided over the function. Concurrently, an exhibition on agri-technologies is also organized on the theme “Innovative Technologies go Commercial” in which CMFRI product Cadalmin Green Algal Extract (GAe) has been exhibited as ICAR technology.
 
     
   
     
  Dr. Charan Das Mahantji, Hon’ble Minister of State for Agriculture and Food Processing Industries, Govt. of India launching Central Marine Fisheries Research Institute’s Cadalmin Green Algal extract (Cadalmin GAe) at 83rd AGM of the ICAR Society at NASC. Shri Sharad Pawarji, Hon’ble Union Minister of Agriculture and Food Processing Industries and President of the ICAR Society, Shri Harish Rawatji, Minister of State for Agriculture and Food Processing Industries and Parliamentary Affairs, and Dr. S. Ayyappan, Hon’ble Secretary, DARE and Director General, ICAR are also seen.

Packsize of the product: 60 capsules (0.5 g active ingredient in each capsule). The product doesn’t contain any ingredient that is classified as an endangered species and the product is registered with local license in Kerala

For any further information please visit: http://www.cmfri.org.in/videogallery.html

MoU signed between CMFRI and Celestial Biolabs Limited, Hyderabad for commercial production and marketing of Cadalmin Green Algal extract in the presence of Dr. S. Ayyappan, Secretary, DARE and Hon’ble Director General, ICAR

Dr. G. Syda Rao, Director, Central Marine Fisheries Research Institute (CMFRI) and Dr. A.N. Singh, Managing Director, Celestial Biolabs limited, Hyderabad signed a Memorandum of Understanding (MoU) in the gracious presence of Dr. S. Ayyappan, Secretary, DARE and Hon’ble Director General, ICAR for commercial production and marketing of Cadalmin Green Algal extract (Cadalmin GAe). Shri Arvind R. Kaushal, Additional Secretary, DARE and Secretary, ICAR, Dr. K.M.L. Pathak, DDG, Animal Science, Dr. M.M. Pandey, DDG, Engineering, Dr. S.K. Datta, DDG, Crop Sciences, Dr. B. Meenakumari, DDG, Fisheries, Dr. Gaya Prasad, ADG, Animal Health and Director, IVRI and Dr AK Vasisth, ADG, PIM/ESM were also present on the occasion.

Cadalmin GAe contains 100% natural marine bioactive anti-inflammatory ingredients extracted from selected marine macroalga by a patented technology. The product is effective to combat arthritic pain and inflammatory diseases in human beings. The active principles in Cadalmin GAe competitively inhibit pro-inflammatory mediators, resulting in decreased production of inflammatory prostaglandins and leukotrienes, and its activity was found to be superior to some of the synthetic non steroidal anti-inflammatory drugs available in the market. Animal model experiments proved the efficiency and safety of this nutraceutical. Time dependent in vivo animal model studies on mammalian subjects revealed the inhibition of inflammatory response to the tune of 73-76% by Cadalmin GAe and its active components as compared to a maximum of 70% for the popular painkiller aspirin that was reported to induce an adverse effect on various human metabolic and physiological parameters. Cadalmin GAe suppresses the edema produced by histamine, and exhibits its anti-inflammatory action by means of either inhibiting the synthesis, release or action of anti-inflammatory mediators. The mean lethal dose (LD50) of Cadalmin GAe was found to be greater than 4000 mg/kg body weight of the mammalian subjects that indicate the safety of the product. As part of the further safety assessment of the extract, feeding of Cadalmin GAe even at a dose upto 2500 mg/kg body weight did not induce significant change in body weights, hematological indices, histopathological, and serum biochemical parameters between the control and treated groups indicating that it has no toxicity to the experimental animals.

Cadalmin GAe distributed to more than 400 patients suffering with chronic joint pain and arthritis, and questionnaire and clinical trial-based studies revealed that more than 98% of the respondents consumed Cadalmin GAe were satisfied with the product with about 70-85% relief in joint pain and arthritis. None of the respondents reported any side effects. The diagnostically useful autoantibody termed as Rheumatoid Factors (RFs), which are the most useful prognostic marker for rheumatoid arthritis significantly reduced from more than 300 IU/mL to less than 20-35 IU/mL within a period of two months of consuming the product.

Cadalmin GAe is a pure natural and 100% vegetarian product, with its therapeutic values, is an import substitute for synthetic drugs. Being a 100% natural product Cadalmin GAe has a promising consumer appeal, and market potential especially for the large vegetarian population in India and abroad. The unique biochemical engineering techniques adopted to retain the anti-inflammatory activities in the preparation of Cadalmin GAe assures higher shelf life. Detailed evaluation using laboratory animal models proved that Cadalmin GAe could be safely taken without any side effects, providing relief to people suffering from arthritis and joint pain. The hygienically processed active ingredients are housed in low moisture content 100% plant-based Naturecaps capsules that meet the dietary or cultural needs of customers that follow a vegetarian lifestyle.

This product will be commercially produced and marketed by Celestial Biolabs Limited, a GMP/ WHO certified pharmaceutical Company based at Hyderabad.